Cynata Therapeutics Limited
CYYNF
$0.118
$0.01615.69%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -2.74% | 970.71% | |||
| Total Revenue | -2.74% | 970.71% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -2.74% | 970.71% | |||
| SG&A Expenses | -2.75% | 218.92% | |||
| Depreciation & Amortization | -2.84% | -0.87% | |||
| Other Operating Expenses | -2.76% | 78.52% | |||
| Total Operating Expenses | -2.75% | 4.68% | |||
| Operating Income | 2.75% | 34.77% | |||
| Income Before Tax | 2.75% | 28.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.75% | 28.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.75% | 28.68% | |||
| EBIT | 2.75% | 34.77% | |||
| EBITDA | 2.75% | 35.63% | |||
| EPS Basic | 1.52% | 30.53% | |||
| Normalized Basic EPS | 2.44% | 31.67% | |||
| EPS Diluted | 1.52% | 30.53% | |||
| Normalized Diluted EPS | 2.44% | 31.67% | |||
| Average Basic Shares Outstanding | 0.00% | 2.54% | |||
| Average Diluted Shares Outstanding | 0.00% | 2.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||